

VIEKIRA PAK (ombitasvir/paritaprevir/ritonavir, dasabuvir)

All coverage requests are reviewed by a Blue Shield clinician.

Coverage is provided when patients meet the following requirements:

1. Age 18 years and older, and
2. Currently has detectable serum Hepatitis C virus (HCV) RNA, and
3. Hepatitis C regimen is prescribed by an appropriate specialist in the care of patients with Hepatitis C (hepatologist, gastroenterologist, infectious disease), and
4. Will not be used together with another direct anti-viral drug (*Olysio, Sovaldi, Viekira, etc.*) to treat HCV infection, and
5. Patient has not been treated with a NS5A inhibitor (daclatasvir, ledipasvir, ombitasvir, elbasvir) containing therapy in the past, and
6. Patient has not been treated with a sofosbuvir-containing regimen in the past, and
7. Viekira dose does not exceed the FDA label recommended maximum daily dose, and
8. Prescribed Hepatitis C regimen is aligned to nationally recognized treatment guidelines, and
9. Patient does not have decompensated liver cirrhosis (METAVIR F4 with Child-Pugh score B or C), and
10. Specific coverage requirements by subpopulations below:

For Genotype-1a/1b (not post-liver transplant):

- a) For genotype-1a patients: Used in combination with ribavirin, and
- b) Patient has a specific contraindication to Harvoni therapy that is not also expected with a Viekira containing regimen.

Coverage: (claims limited to 30-day supply per prescription)

Genotype	Evidence of Cirrhosis	Treatment (weeks)
1a	no	12
1b	No	12
1b	yes	12
1a	yes	24

For Genotype-1 (post-liver transplant):

- a) Used in combination with ribavirin only, and
- b) Patient does not have liver cirrhosis (METAVIR F4)), and
- c) Patient has a specific contraindication to Harvoni with ribavirin therapy that is not also expected with a Viekira containing regimen.

Coverage: 24 weeks (claims limited to 30-day supply per prescription)

Treatment Regimen & Duration table:

HCV population	AASLD/IDSA recommended regimen	Duration of Treatment
----------------	--------------------------------	-----------------------

not post-liver transplant:			
genotype 1a	without cirrhosis	Viekira + ribavirin	12 weeks
	with cirrhosis	Viekira + ribavirin	24 weeks
genotype 1b		Viekira	12 weeks
post-liver transplant:			
genotype 1	without cirrhosis	Viekira + ribavirin	24 weeks

American Association for the Study of Liver Diseases (AASLD), Infectious Diseases Society of America (IDSA)

Effective: 06/02/2021